<DOC>
	<DOCNO>NCT00414947</DOCNO>
	<brief_summary>This study evaluate bioequivalence well rate extent absorption vildagliptin tablet manufacture Beijing Novartis Pharma Ltd. compare import vildagliptin tablet Chinese healthy volunteer . This trial recruit patient United States ,</brief_summary>
	<brief_title>Bioequivalence Vildagliptin Tablet Manufactured China Compared Imported Vildagliptin Tablet Chinese Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>Chinese healthy male subject age 18 40 year age include In good health Male subject use doublebarrier local contraception entire duration study study completion visit refrain father child three month follow last study drug administration . Body mass index within range 19 24 kg/m2 weigh least 50 kg Smokers Use prescription drug within 4 week prior dose , overthecounter medication ( vitamin , herbal supplement , dietary supplement ) within 2 week prior dose . Paracetamol acceptable . Participation clinical investigation within 4 week prior dose . Donation loss 400 ml blood within 8 week prior first dose , longer required local regulation . Significant illness within two week prior dose . A past personal close family medical history clinically significant cardiac abnormality . History : Fainting , low blood pressure standing , irregular heartbeat , Acute chronic bronchospastic disease ( include asthma chronic obstructive pulmonary disease , treat treat ) , Clinically significant drug allergy history atopic allergy ( asthma , urticaria , eczematous dermatitis ) Known hypersensitivity study drug similar drug Any surgical medical condition might significantly alter absorption , distribution , metabolism excretion drug jeopardize participation study . Immunodeficiency disease , include positive HIV ( ELISA Western blot ) test result . Positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C test result . Drug alcohol abuse within 12 month prior dose Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>safety</keyword>
	<keyword>LAF237</keyword>
	<keyword>vildagliptin</keyword>
	<keyword>Chinese</keyword>
	<keyword>healthy subject</keyword>
</DOC>